Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

Affiliations

¹ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
² Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano.
³ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France.
⁴ Department of Pathology, Istituto Europeo di Oncologia, Milano Faculty of Medicine, University of Milan, Milano.
⁵ Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
⁶ Division of Pathology, Modena University Hospital, Modena, Italy.
⁷ Departments of Medical Biology and Pathology.
⁸ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif.
⁹ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif Faculty of Medicine, Paris Sud University, Kremlin-Bicêtre, France.

Published Erratum

M V Dieci et al. Ann Oncol. 2015 Jul.

. 2015 Jul;26(7):1518.

doi: 10.1093/annonc/mdv241.

¹ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
² Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano.
³ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France.
⁴ Department of Pathology, Istituto Europeo di Oncologia, Milano Faculty of Medicine, University of Milan, Milano.
⁵ Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
⁶ Division of Pathology, Modena University Hospital, Modena, Italy.
⁷ Departments of Medical Biology and Pathology.
⁸ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif.
⁹ INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif Faculty of Medicine, Paris Sud University, Kremlin-Bicêtre, France.

No abstract available

Erratum for

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.